CA
LXEO icon

Cliff Asness’s Lexeo Therapeutics LXEO Stock Holding History

Cliff Asness’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
256,661
-82,962
-24% -$449K ﹤0.01% 2903
2026
Q1 		$1.95M Buy
339,623
+2,237
+0.7% +$15.9K ﹤0.01% 2365
2025
Q4 		$3.35M Sell
337,386
-10,537
-3% -$96.2K ﹤0.01% 1815
2025
Q3 		$2.31M Buy
347,923
+159,288
+84% +$770K ﹤0.01% 1895
2025
Q2 		$758K Buy
188,635
+138,298
+275% +$455K ﹤0.01% 2364
2025
Q1 		$175K Buy
50,337
+39,627
+370% +$176K ﹤0.01% 2916
2024
Q4 		$70.5K Buy
+10,710
New +$84.4K ﹤0.01% 2792

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Cliff Asness's LXEO Position: Q2 2026 in Review

Cliff Asness reduced its Lexeo Therapeutics (LXEO) stake by 24% in Q2 2026, selling an estimated $449K and leaving 256,661 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Cliff Asness first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.35M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Cliff Asness held 256,661 shares of Lexeo Therapeutics worth $1.19M as of Q2 2026.
  • Cliff Asness sold 82,962 Lexeo Therapeutics shares in Q2 2026, an estimated $449K.
  • Lexeo Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2903 holding.
  • Cliff Asness first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Cliff Asness's Lexeo Therapeutics position peaked at $3.35M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.